Rhythm Pharmaceuticals, Inc. RYTM

-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediat

Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare n

NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.

Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up about 7x over 5 years, which puts extra focus on whether recent gains already reflect much of the company story. Approval of IMCIVREE for acquired hypothalamic obesity in Japan may support expectations for future revenue growth, while execution risk around pricing, uptake...

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17. “We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseas

-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the marketing